The Cas9/KrasG12D coding plasmid can be delivered by MSC to synergistic subcutaneous tumor cells to remove the DNA associated with the mutated Kras gene in tumor cells after the injection of exosomes, reducing ERK signaling and cell proliferation [147]. Here, KRAS is linked to neoplasm.